Coherus Biosciences | CHRS - Operating Expenses


Coherus Biosciences reported $51.83M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.27B 538M Mar/2026
Acadia Pharmaceuticals USD 272.68M 6.08M Mar/2026
Akebia Therapeutics USD 63.08M 8.26M Dec/2025
ALKERMES USD 1.75B 1.43B Mar/2026
Alnylam Pharmaceuticals USD 898.54M 66.78M Mar/2026
Amarin USD 51.48M 113K Dec/2025
Amgen USD 4.78B 1.12B Mar/2026
Baxter International USD 6.04B 2.85B Mar/2026
Biogen USD 1.96B 69.6M Mar/2026
BioMarin Pharmaceutical USD 636.56M 39.61M Mar/2026
Bristol-Myers Squibb USD 20.07B 11.77B Mar/2026
Coherus Biosciences USD 51.83M 2.48M Dec/2025
Eli Lilly USD 10.02B 285M Mar/2026
Fujifilm JPY 825.49B 58.1B Mar/2026
Gilead Sciences USD 23.52B 18.55B Mar/2026
Ironwood Pharmaceuticals USD 57.33M 8.63M Dec/2024
Merck USD 18.17B 8.01B Mar/2026
Myriad Genetics USD 212.8M 16.2M Dec/2025
Pacira USD 172.75M 20.93M Mar/2026
Perrigo USD 935.6M 89.6M Mar/2026
Pfizer USD 90.1B 77.19B Mar/2026
PTC Therapeutics USD 226.66M 19.64M Mar/2026
Regeneron Pharmaceuticals USD 31.42B 28.44B Mar/2026
Sarepta Therapeutics USD 372.37M 480.65M Mar/2026
Teva Pharmaceutical Industries USD 3.22B 1000M Mar/2026
Vertex Pharmaceuticals USD 1.85B 78.6M Mar/2026
Xencor USD 82.38M 513K Mar/2026
Zoetis USD 3.23B 1.68B Mar/2026